Decrease of subcutaneous adipose tissue lipolysis after exposure to hypoxia during a simulated ascent of Mt Everest.
The purpose of this study was to examine the effects of prolonged hypoxia on adipose tissue lipolysis, in relation to the weight loss usually observed at high altitude. Eight male subjects were exposed for 31 days to gradually increasing hypobaric hypoxia up to the equivalent altitude of 8848 m (Mt Everest) in a decompression chamber, after 7 days at 4350 m for altitude pre-acclimatization. A biopsy of subcutaneous adipose tissue was performed before and after hypoxic exposure, to study in vitro changes in adipose tissue sensitivity. Fat mass, adipocyte volume and spontaneous lipolysis were not impaired by the exposure to hypoxia. The in vitro lipolytic response to epinephrine, isoproterenol, growth hormone (GH) and parathormone (PTH) decreased significantly (P<0.01, P<0.05, P<0.01 and P<0.01 respectively), as did the plasma concentration of free fatty acid (P<0.01). The anti-lipolytic effect promoted by alpha2-adrenergic receptor stimulation (epinephrine with propranolol) was greater after hypoxia (P<0.05), while the anti-lipolytic activity of insulin was decreased (P<0.01). In conclusion, prolonged exposure to hypobaric hypoxia led to a potent reduction in lipid mobilization, through a decrease in the efficiency of beta-adrenergic, GH and PTH lipolytic pathways, as well as an increment in the alpha2-adrenergic-receptor-mediated anti-lipolytic effects.
de Glisezinski
I
I
Laboratoire des Adaptations de l'Organisme à l'Exercice Musculaire, Unité INSERM U317, C.H.U. Purpan, Toulouse, France.
Crampes
F
F
Harant
I
I
Havlik
P
P
Gardette
B
B
Jammes
Y
Y
Souberbielle
J C
JC
Richalet
J P
JP
Rivière
D
D
D000273:Adipose Tissue / Q000378:metabolism*; D000322:Adrenergic Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000531:Altitude; D001823:Body Composition / Q000502:physiology; D004837:Epinephrine / Q000494:pharmacology; D019382:Human Growth Hormone / Q000494:pharmacology; D006801:Humans; D000860:Hypoxia / Q000378:metabolism*; D007202:Indicators and Reagents; D007545:Isoproterenol / Q000494:pharmacology; D008066:Lipolysis / Q000502:physiology*; D008297:Male; D009051:Mountaineering / Q000502:physiology*; D010281:Parathyroid Hormone / Q000494:pharmacology
D000322:Adrenergic Agonists; D000318:Adrenergic beta-Agonists; D007202:Indicators and Reagents; D010281:Parathyroid Hormone; D019382:Human Growth Hormone; D007545:Isoproterenol; D004837:Epinephrine